<DOC>
	<DOCNO>NCT02014337</DOCNO>
	<brief_summary>This study ass safety combination mifepristone eribulin patient metastatic locally advance unresectable breast specify solid tumor , determine preliminary efficacy combination mifepristone eribulin patient metastatic locally advance unresectable Triple Negative Breast Cancer ( TNBC ) . The structure study single arm , non-randomized , open-label , multicenter trial control group . The study conduct 11 site , 40 evaluable patient</brief_summary>
	<brief_title>Mifepristone Eribulin Patients With Metastatic Triple Negative Breast Cancer Other Specified Solid Tumors</brief_title>
	<detailed_description>There two part study : Part 1 , dose escalation phase , MTD RP2D determine 20 patient metastatic breast specify solid tumor , regardless receptor status ; Part 2 , dose expansion phase preliminary estimate efficacy make expansion group 20 patient glucocorticoid receptor-positive metastatic TNBC RP2D . Treatment administer 21-day cycle , exception first cycle , 28 day duration lead-in 7 day dose mifepristone . Cycle 1 ( 28-day cycle ) : Mifepristone administer orally ( PO ) food daily 28 day . Eribulin administer intravenously ( IV ) 2 5 minute day 8 15 . Cycle 2 beyond ( 21-day cycle ) : Mifepristone administer orally ( PO ) food daily 21 day . Eribulin administer intravenously ( IV ) 2 5 minute day 1 8 . Enrollment Part 2 study ( dose expansion ) occur RP2D determine . Patients dose expansion study must TNBC disease glucocorticoid receptor-positive ( immunohistochemistry [ IHC ] ) . Patients treat repeated 21-day cycle progression another withdrawal criterion meet . Part 1 study complete . Part 2 study ongoing .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>1 . Informed consent give prior studyspecific screening procedure 2 . ≥ 18 year old Part 2 , dose expansion : 1 . Diagnosis TNBC : &lt; 1 % cell positive ER/progesterone receptor , HER2 IHC score 0 1 , FISH HER2+ ratio le 1.8 ; patient low ER IHC ( &gt; 1 % &lt; 10 % cell positive ) , negative genomic assay eligible 2 . Inoperable metastatic locally advanced unresectable disease 3 . Patients receive minimum one , five prior chemotherapy regimens 4 . Must submit diagnostic FFPE tumor tissue sample confirm tumor GR positivity . Tumor tissue may primary metastatic lesion . In absence sufficient tissue complete IHC , tumor biopsy require . 5 . Tumor must glucocorticoid receptor positive TNBC ( ≥10 % positive cell IHC tumor biopsy ) 6 . Must measurable disease ( RECIST v1.1 ) least one lesion previously irradiate unless document evidence progression 7 . Patients treat , stable brain metastasis eligible provide treatment ≥4 week prior initiation study drug , baseline CT MRI negative new brain metastasis . Must require therapy corticosteroid . 8 . ECOG performance status 0 1 9 . Must adequate bone marrow renal/hepatic function screen visit ( ≤7 day precede lab assessment ) : i. ANC ≥ 1,500/mm3 , without GCSF ii . Platelets ≥ 100,000/mm3 , without transfusion iii . Hemoglobin ≥ 9 g/dL , without transfusion support iv . AST ALT ≤ 3 × ULN v. Total serum bilirubin ≤ 1.5 time ULN vi . Serum creatinine ≤ ULN vii . Potassium magnesium level within normal limit . If low limit normal , must level correct supplementation prior start study drug . viii . albumin &gt; 3.0 g/dL 10 . PT/aPIT ≤ 1.5 x ULN 11 . Diseasefree period &gt; 3 year previous malignancy , exclude curatively treat basal cell carcinoma , squamous cell carcinoma skin , carcinoma situ cervix . 12 . Female patient childbearing potential must negative serum pregnancy test . Sexually active patient must willing use nonhormonal contraception , include condom use male partner , barrier method female partner treatment period least 3 month last dose study drug . Females consider childbearing potential include menopause &gt; 2 year , surgically sterile ( status post tubal ligation hysterectomy ) . 13 . Must able willing comply study visit schedule study procedure . 14 . Able take oral medication 1 . Systemic cytotoxic therapy radiotherapy ≤14 day prior day 1 cycle 1 2 . Major surgery within 4 week , minor surgery within 2 week prior day 1 cycle 1 3 . Endometrial bleed 4 . For two week prior day 1 cycle 1 , administration specify cytochrome P450 3A ( CYP3A ) inducers 5 . Patients take simvastatin lovastatin . Patients switch alternative therapy minimum 2 week start study drug 6 . Patients treat investigational agent &lt; 21 day prior day 1 cycle 1 7 . Concomitant use biological agent include growth factor . Exception : 3 6patient breast cancer cohort enrol explore use prophylactic growthfactor support 1.4 mg/m2 dose eribulin . 8 . Patients require treatment systemic corticosteroid serious medical condition illness ( e.g . immunosuppression organ transplantation ) 9 . History significant cardiac disease . Includes second/third degree heart block ; significant ischemic heart disease ; mean QTc interval &gt; 480 msec prior study start ; poorly control hypertension ; congestive heart failure NYHA Class II worse 10 . Pregnant breastfeed 11 . Any significant comorbid condition would impair study participation cooperation 12 . In Part 2 , unable unwilling consent provision tumor tissue GR assay</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mifepristone</keyword>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Carcinoma , transitional cell</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Prostatic neoplasm</keyword>
</DOC>